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Diagnosis of pheochromocytomas and paragangliomas in patients receiving hemodialysis is 
troublesome. The aim of the study was to establish optimal conditions for blood sampling for mass 
spectrometric measurements of normetanephrine, metanephrine and 3-methoxytyramine in patients 
on hemodialysis and specific reference intervals for plasma metanephrines under the most optimal 
sampling conditions. Blood was sampled before and near the end of dialysis, including different 
sampling sites in 170 patients on hemodialysis. Plasma normetanephrine concentrations were lower 
(P < 0.0001) and metanephrine concentrations higher (P < 0.0001) in shunt than in venous blood, with 
no differences for 3-methoxytyramine. Normetanephrine, metanephrine and 3-methoxytyramine 
concentrations in shunt and venous blood were lower (P < 0.0001) near the end than before 
hemodialysis. Upper cut-offs for normetanephrine were 34% lower when the blood was drawn 
from the shunt and near the end of hemodialysis compared to blood drawn before hemodialysis. 
This study establishes optimal sampling conditions using blood from the dialysis shunt near the 
end of hemodialysis with optimal reference intervals for plasma metanephrines for the diagnosis of 
pheochromocytomas/paragangliomas among patients on hemodialysis.
Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors derived from the chromaffin cells 
of the adrenal medulla or extra-adrenal chromaffin  tissue1. Although rare, these tumors constitute an important 
endocrine cause of  hypertension2. Current clinical practice guidelines stipulate that biochemical screening for 
PPGLs should include measurements of either plasma free or urinary fractionated  metanephrines3. Additional 
measurements of 3-methoxytyramine are useful for identifying occasional tumors that predominantly produce 
 dopamine4.
In patients with advanced renal insufficiency, the diagnostic work up of PPGLs is troublesome. Similar to 
patients with PPGLs, many patients with end-stage renal disease (ESRD) on hemodialysis (HD) suffer from 
hypertension with wide swings in blood pressure. Biochemical confirmation or exclusion of PPGLs in such 
patients is confounded by the effects of impaired renal function on the elimination of catecholamines and their 
metabolites in  urine5,6. However, as the circulatory clearance of plasma free metanephrines is relatively independ-
ent of renal  function7, measurements of these compounds in plasma might be preferred in patients with ESRD. 
Yet, increases of plasma free metanephrines have been reported in up to 25–28% of patients on  HD8–10, possibly 
reflecting CKD-associated activation of the sympathetic nervous  system11,12.
We have recently published cut-offs for normetanephrine (NMN), metanephrine (MN) and 3-methoxyt-
yramine (3-MTY) plasma concentrations with the use of liquid chromatography-tandem mass spectrometry 
(LC–MS/MS) in patients with CKD stage III, IV from morning peripheral venous blood samples and in patients 
on HD from morning peripheral venous blood samples, before the beginning of  HD13. However, the influence 
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of HD on the assessment of plasma metanephrines has not been studied to date. Importantly, it is not yet clari-
fied if modifications of blood sampling would improve the diagnostic performance of measurements of plasma 
metanephrines in patients receiving HD. As there is a known arterio-venous gradient for plasma metanephrines 
in humans, sampling from the easily accessible shunt rather than from a vein might provide benefits as shunt 
blood closely matches arterial  blood14,15. In addition, the time point of sampling may have a critical influence. 
During HD patients undergo a long period of rest that might be beneficial in terms of minimizing sympatho-
adrenal  activation16. On the other hand, the continued ultrafiltration has the potential to increase sympathetic 
activation during  treatment17,18.
The aim of the study was, therefore, to establish optimal procedures for blood sampling to determine plasma 
concentrations of free metanephrines and 3-methoxytyramine in patients receiving HD.
Methods
Subjects. This study involved analysis of data from 107 patients receiving HD. Patients were enrolled under 
a multicenter prospective study at six clinical care  centers13. The study was approved by local Ethics-Committees 
(Ethics Committee of the Technical University Dresden, Germany and Ethics Committee of the University War-
saw, Poland) and all patients provided written informed consents. All methods were performed in accordance 
with the relevant guidelines and regulations. All patients had an arterio-venous vascular access and were receiv-
ing HD or online hemodiafiltration for at least one year. Subjects were excluded if they presented with unstable 
conditions (sepsis or decompensated heart failure) or medication interfering with primary outcome parameters 
(tricyclic antidepressants, L-DOPA or medication containing sympathomimetic decongestants)19. Baseline char-
acteristics of the participants are reported in Table 1.
Study design. The main goal of the study was to establish optimal conditions for blood sampling for meas-
urements of plasma free metanephrines and 3-methoxytyramine in patients on HD. For this, two blood samples, 
one from the shunt and the other from a contralateral antebrachial vein, were collected from all patients after 
30 min of supine rest before the start of HD and during the last hour of treatment. In a subgroup of 30 patients, 
ninety minutes after start of HD, the ultrafiltration rate was set to zero for 5  min and pre- as well as post-
filter blood samples were drawn from the extracorporeal circuit to determine compound extraction. Patients 
remained in the semi-recumbent position throughout the HD. Duration of HD was approximately 4 h.
Table 1.  Characteristics of patients receiving hemodialysis (HD). a Mean ± standard deviation. b Median-range. 
c ICT intensified insulin treatment. d Systemic disease: HUS, amyloidosis, multiple myelom, lupus, vasculitis. 
e Other: toxicity, medication, kidney tumor, hepatocardiorenal syndrome.
Number (n) 107
Female (%) 31.5
Age (years) 65.1 ± 14.3
BMI (kg/m2) 28.4 ± 7.5a
Hypertension 79.4%
Systolic blood pressure (mmHg) 137.7 ± 21.3a
Diastolic blood pressure (mmHg) 73.7 ± 12.3a
Hypertensive patients using antihypertensives (%) 98.1
Patients on beta-blocker (%) 83.5
Patients on ARBs/ACEi (%) 63.5
Diabetes type II (%) 38.3
ICTc treatment (%) 26.0
Causes of HD
Diabetic and hypertensive kidney disease (%) 51.4%
Chronic glomerulonephritis (%) 21.5%
Polycystic kidney disease (%) 10.3%
Systemic  diseased (%) 5.6%
Chronic pyelonephritis (%) 5.6%
Othere (%) 5.6%
Hematocrit % 0.36 (0.26–0.44)b
GFR (mL/min) 7.3 ± 7.1a
Creatinine (µmoL/L) 745.9 ± 257.4
Urea (mmoL/L) 22 ± 5.4
Dialysis flow (mL/min) 300 (105–430)b
Plasma flow (mL/min) 192 (62–275)b
Clearance of metanephrines (mL/min) 78 (22–105)b
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Laboratory analysis. Measurements of plasma free NMN, MN and MTY concentrations were performed 
using LC–MS/MS20. All patients were instructed to fast and refrain from alcohol, nicotine, decaffeinated and 
caffeinated beverages for 12 h before the first sampling. A low amine diet was allowed during dialysis procedures 
prior to the second dialysis blood sampling, in a semi-recumbent position, whereas catecholamine containing 
foods were avoided. Blood samples were kept on ice until plasma was separated and stored frozen at − 80 °C 
before analyses.
Statistical analysis. Statistical analyses utilized the JMP statistics software package (SAS Institute Inc, 
Cary, NC), with comparisons by Wilcoxon´s paired and Mann–Whitney U unpaired tests. Reference intervals 
for metabolites were established from distributions of the measured variables in populations with CKD receiving 
HD using non-parametric or parametric approaches as indicated by the nature of distributions. Upper cut-offs 
of reference intervals were determined by 97.5% percentiles of the distributions of each metabolite. Using the 
medians of the dialysis flow and the hematocrit, the plasma flow was calculated {= Blood Flow × (1 − Ht)}. From 
the dialysis plasma flow and the difference in concentrations of metanephrines before vs after the blood leaves 
the filter, the dialysis clearance was then calculated {= Plasma flow ×  [Cmetabolitebeforefilter −  Cmetaboliteafterfilter/
Cmetabolitebeforefilter]}.
Results
Patient characteristics. Hypertension was recorded in 79.4% of patients receiving HD and up to 98.1% 
received hypertension treatment. Up to 63.5% were treated with ACE inhibitors or ARBs and up to 83.5% with 
ß-blockers. Diabetes was present in 38.3% of patients. The proportion of patients treated with intensified insulin 
treatment (ICT) was 26%. Impaired renal function was mainly due to diabetic and hypertensive kidney disease, 
followed by glomerulonephritis and polycystic kidney disease (Table 1).
Optimal conditions for blood sampling in patients on HD. Pre‑ versus end of dialysis. Norme-
tanephrine and metanephrine concentrations, both in venous and shunt blood (Fig. 1A,B), were lower near the 
end than before dialysis (P < 0.0001). Similarly, concentrations of 3-methoxytyramine tended to be lower near 
the end than before dialysis, both in venous (P = 0.050) and shunt blood (P = 0.062), but failed to reach statistical 
significance (Fig. 1A,B).
Clearance of metanephrines and 3‑methoxytyramine by the dialysis filter. Among patients receiving HD there 
were lower plasma concentrations of normetanephrine (P < 0.0001), metanephrine (P < 0.0001) and 3-methoxy-
tyramine (P = 0.0014) in blood leaving than entering the dialysis filter (Fig. 2). The medians of dialysis clearance 
for NMN (79.7 mL/min) and MN (76.5 mL/min) were similar. The dialysis clearance of both metanephrines 
was, therefore, calculated to approximately 78  mL/min (Table 1), representing only 6.5% of the endogenous 
clearance of plasma metanephrines in patients with ESRD, which is assumed to reach 1200 mL/min21,22.
Shunt versus venous blood sampling. For blood samples drawn near the end of dialysis, plasma normetanephrine 
concentrations among patients on HD were significantly lower (P = 0.005) and metanephrine concentrations 
higher (P < 0.0001) in shunt than in venous blood, with no significant difference for 3-methoxytyramine (Fig. 3).
HD-specific reference intervals under optimal sampling conditions. Due to the high number of 
outliers involving remarkably high plasma concentrations of 3-MTY in patients with ESRD, HD-specific cut-off 
values are recommended only for plasma metanephrines. Compared to already established stage IV/HD specific 
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Figure 1.  Δ of plasma concentrations of free normetanephrine (NMN), metanephrine (MN) and 
3-methoxytyramine (3-MTY) before versus near the end of HD, in shunt (A) and in vein (B).
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NMN in patients on HD were 34% lower when the blood was drawn from the shunt near the end of HD than 
from the vein before HD. In contrast, upper cut-off levels for MN were 12% higher when the blood was drawn 
from the shunt near the end of HD than from the vein before HD (Table 2).
Discussion
The present study establishes that measurements of plasma metanephrines in patients receiving HD are most 
appropriate using blood drawn from shunt at a time near the end of dialysis (Box 1). Moreover, this study outlines 
specific upper cut-offs of reference intervals for plasma metanephrines under these most optimal conditions in 
patients on HD that can be expected to minimize false positive results.
The diagnostic work-up of patients suspected of harboring a PPGL among patients on HD is a clinical chal-
lenge. Consequently, reliable biochemical tests to exclude or confirm these tumors are crucial. Urinary tests are 
clearly unreliable for patients on  HD5,6, while for plasma free metanephrines the reported prevalence of false 
positive results had varied from 85% using high pressure liquid chromatography-electrochemical detection 
(HPLC-ED)12 to approximately 10.2% for NMN and 14% for MN when using LC–MS/MS, confirming the 
superiority of this method, particularly in terms of relative freedom of analytical  interferences13. However, the 
remaining relatively high prevalence of false positive results for either elevation of NMN or MN likely reflects 
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Figure 2.  Δ of plasma concentrations of free normetanephrine (NMN), metanephrine (MN) and 
3-methoxytyramine (3-MTY) before the blood enters the filter versus after leaving it.
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Figure 3.  Δ of plasma concentrations of free normetanephrine (NMN), metanephrine (MN) and 
3-methoxytyramine (3-MTY) in the venous versus shunt blood, near the end of HD.
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chronic activation of the sympathetic nervous system, which characterizes patients with  ESRD8,9. The kidneys 
are responsible for 14 to 16% of the circulatory clearance of plasma free  metanephrines21, so that some smaller 
increase in plasma concentrations can also be expected to result from impaired renal function.
The above considerations highlight the need for optimized pre-analytical procedures and specific upper 
limits of reference intervals under most optimal sampling conditions. With recognition of the above needs, the 
main aim of our study was to establish the most appropriate sampling conditions for measurements of plasma 
metanephrines and 3-MTY during HD. Due to the high number of outliers involving remarkably high levels 
of 3-MTY in patients on HD, optimized pre-analytical procedures and specific upper cut-offs were focused on 
plasma metanephrines. The lower plasma concentrations of metanephrines, both in venous and shunt blood, 
near the end rather than before starting HD indicate the former time point as preferable to minimize false posi-
tive results. The prolonged recumbency (4 h HD duration) could provide one  explanation16 while an effect of the 
dialysis filter to increase clearance of metanephrines likely also contributes to the lowered concentrations towards 
the end of dialysis. Nevertheless, fractional extractions of metanephrines by the dialysis filter were calculated to 
contribute to less than 7% of the endogenous clearance of metanephrines in patients on HD.
In addition to showing that the last hour of dialysis is the most appropriate time for blood sampling, the 
present study also established the shunt as the best sampling site. This conclusion was based on the findings that 
plasma concentrations of NMN were lower and those of MN higher in shunt than in venous blood. The latter 
observation can be explained by extraction of this metabolite during passage from arterial to venous sites result-
ing in a physiologic arterio-venous concentration  gradient21,23,24. NMN is also extracted during passage from 
arterial to venous sampling sites, but, in contrast to MN, it is also generated by metabolism of locally produced 
 norepinephrine10. As false positive results are much more prevalent for NMN and the same metabolite is the 
most important for the diagnosis of PPGLs, the dialysis shunt represents the most appropriate sampling site to 
both minimize false-positive results for NMN, and detect any signal for both metabolites from catecholamine-
producing tumors.
Our study, like all previous studies, has limitations. The present study did not include patients on HD with 
PPGLs, as such patients are extremely rare. Another limitation is that we can not definitely exclude the pos-
sibility that any of our patients actually harbors a PPGL. If some of our patients, though, would harbor a PPGL, 
one would expect that this would be uncovered by the development of signs and symptoms related to tumoral 
catecholamines. All the patients had clinical follow up for at least 4 years, and none of them showed any signs 
of PPGLs. We, therefore, assume that the presence of a tumor in some of the patients of our study is extremely 
unlikely.
A final limitation of our study is that we did not include patients on continuous ambulatory peritoneal dialysis 
(CAPD) or on “pure” hemofiltration. Patients on CAPD do not usually have arterio-venous fistula and “pure” 
hemofiltration is not a common type of dialysis among patients with end stage renal disease. In our cohort, 
though, apart from patients with HD we have included twelve patients on online-hemodiafiltration, who showed 
no significant differences in pre-, post-filter or near the end of HD concentrations of plasma metanephrines, 
compared to patients on HD (Supplementary figures). In that respect, we assume that convective solute and 
diffuse transport modify metanephrine levels in a similar way.
Conclusion
This study is important in being the first to comprehensively address optimal sampling conditions using blood 
from the dialysis shunt near the end of HD with optimal reference intervals for plasma metanephrines for the 
diagnosis of PPGLs among patients on HD. Our study thereby provides immediate guidance to clinicians in 
daily routine practice.
Table 2.  HD specific cut-offs (97.5% percentiles) for plasma metanephrines for patients on HD when the 
blood is drawn from the vein and before HD versus the shunt, near the end of HD.
Patients on HD
Vein before HD Shunt near the end of HD
Normetanephrine (nmol/L)
Median 0.649 0.451
2.5 Percentile 0.181 0.131
97.5 Percentile 1.622 1.055
Metanephrine (nmol/L)
Median 0.231 0.191
2.5 Percentile 0.092 0.064
97.5 Percentile 0.417 0.472
Methoxytyramine (nmol/L)
Median 0.075 0.043
2.5 Percentile 0.019 0.007
97.5 Percentile 0.896 0.653
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